{"id":71421,"date":"2026-05-20T10:30:00","date_gmt":"2026-05-20T10:30:00","guid":{"rendered":"https:\/\/medsbase.com\/5-amino-1mq\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"5-amino-1mq","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/5-amino-1mq\/","title":{"rendered":"5-Amino-1MQ (5-Amino-1-Metilquinol\u00ednio Iodeto)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 o 5-Amino-1MQ?<\/h3>\n<p style=\"margin: 0;\"><strong>5-Amino-1MQ<\/strong> (iodeto de 5-amino-1-metilquinol\u00ednio, CAS 42464-96-0) \u00e9 uma pequena mol\u00e9cula seletiva do local do substrato <strong>Inibidor da NNMT (nicotinamide N-methyltransferase)<\/strong> com um IC publicado<sub>50<\/sub> de 1,2 \u00b5M. Ao bloquear a NNMT \u2014 a enzima citos\u00f3lica que consome tanto a nicotinamida (o precursor do NAD<sup>+<\/sup>) como a S-adenosil-L-metionina (SAM, o dador universal de metilo) \u2014 o 5-Amino-1MQ foi reportado em estudos revistos por pares como aumentando os n\u00edveis intracelulares de NAD<sup>+<\/sup> e SAM, reduzindo a lipog\u00e9nese em adip\u00f3citos 3T3-L1, e demonstrando efic\u00e1cia in vivo em modelos murinos de obesidade induzida por dieta (20 mg\/kg\/dia), repara\u00e7\u00e3o mediada por c\u00e9lulas estaminais musculares, e met\u00e1stase de cancro do ov\u00e1rio, sem efeitos adversos at\u00e9 60 mg\/kg\/dia. \u00c9 uma pequena mol\u00e9cula (<em>n\u00e3o \u00e9 um pept\u00eddeo<\/em>) supplied as a lyophilized powder.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sal quatern\u00e1rio de am\u00f3nio quinolinium de pequena mol\u00e9cula; inibidor seletivo da NNMT; <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Iodeto de 5-Amino-1-metilquinolinium<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">42464-96-0<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>10<\/sub>H<sub>11<\/sub>IN<sub>2<\/sub> (sal de iodeto)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">286,11 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mechanism<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Inibidor seletivo do local do substrato da nicotinamide N-methyltransferase (NNMT); IC<sub>50<\/sub> = 1,2 \u00b5M (ensaio: 50 \u00b5M SAM, 100 \u00b5M nicotinamida). N\u00e3o inibe metiltransferases relacionadas (GNMT, PNMT, COMT) ou enzimas de salvamento de NAD<sup>+<\/sup>-enzimas de salvamento (NAMPT, NMNAT).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/d (sal quinolinium de pequena mol\u00e9cula \u2014 n\u00e3o \u00e9 um p\u00e9ptido)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized crystalline \/ powder (off-white to pale yellow); supplied in single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA dispon\u00edvel mediante pedido) \u2014 corresponde ao grau de refer\u00eancia Sigma-Aldrich SML2832<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Altamente sol\u00favel em \u00e1gua (o sal de am\u00f3nio quatern\u00e1rio \u00e9 hidrof\u00edlico). Reconstitui-se facilmente em \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril ou PBS em concentra\u00e7\u00f5es at\u00e9 ~50 mg\/mL sem precipita\u00e7\u00e3o. Tamb\u00e9m sol\u00favel em DMSO para prepara\u00e7\u00e3o de stock em cultura de c\u00e9lulas in vitro.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C para stock de trabalho a curto prazo; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos (est\u00e1vel \u226536 meses a \u221220 \u00b0C). Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar dentro de ~30 dias. Proteger da exposi\u00e7\u00e3o prolongada \u00e0 luz. Evitar ciclos repetidos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o de solu\u00e7\u00f5es de trabalho.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 o 5-Amino-1MQ?<\/h2>\n<p><strong>5-Amino-1MQ<\/strong> (iodeto de 5-amino-1-metilquinol\u00ednio, CAS 42464-96-0) \u00e9 um inibidor seletivo de pequena mol\u00e9cula de <strong>nicotinamida N-metiltransferase (NNMT)<\/strong>, uma enzima metiltransferase citos\u00f3lica cuja biologia emergiu na \u00faltima d\u00e9cada como um n\u00f3 que conecta o metabolismo do eixo NAD<sup>+<\/sup>, lipog\u00e9nese em adip\u00f3citos, biologia de c\u00e9lulas estaminais musculares e metabolismo estromal do cancro. \u00c9 <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em> \u2014 \u00e9 um sal de am\u00f3nio quatern\u00e1rio de quinol\u00ednio sint\u00e9tico com a f\u00f3rmula molecular C<sub>10<\/sub>H<sub>11<\/sub>IN<sub>2<\/sub> and a molecular weight of 286.11 g\/mol (as the iodide salt). MedsBase stocks it in the same lyophilized-vial format as our peptide catalogue for convenience of reconstitution and dosing in mixed-protocol studies. NNMT catalyses the transfer of a methyl group from <strong>S-adenosil-L-metionina (SAM)<\/strong> \u2014 o dador universal de metilo celular \u2014 para <strong>nicotinamida<\/strong>, gerando 1-metilnicotinamida (1-MNA) e S-adenosilhomociste\u00edna (SAH). A rea\u00e7\u00e3o consome terminalmente ambos os substratos: nicotinamida (que de outra forma seria reciclada em NAD<sup>+<\/sup> pela NAMPT), e SAM (que de outra forma estaria dispon\u00edvel para as centenas de rea\u00e7\u00f5es de metila\u00e7\u00e3o celular realizadas por outras metiltransferases). O NNMT situa-se, portanto, na intersec\u00e7\u00e3o de dois dos eixos mais estudados da bioqu\u00edmica celular \u2014 a via de reciclagem do NAD<sup>+<\/sup> salvage pathway and one-carbon \/ methylation metabolism \u2014 and its expression is markedly elevated in obesity-associated adipose tissue, cancer stroma, and aged skeletal muscle. 5-Amino-1MQ is the most-published <strong>pequena mol\u00e9cula, direcionado ao local do substrato<\/strong> mais publicado na \u00e1rea. Foi caracterizado por Neelakantan et al. (2017\u20132018) como um inibidor seletivo com um IC<sub>50<\/sub> de 1,2 \u00b5M contra o NNMT recombinante, sem atividade off-target contra metiltransferases relacionadas (GNMT, PNMT, COMT) ou enzimas de reciclagem de NAD<sup>+<\/sup>-salvage enzymes (NAMPT, NMNAT), and oral bioavailability sufficient to support in-vivo rodent dosing protocols. Subsequent in-vivo has documented activity in three independent disease-relevant model systems: diet-induced obesity, skeletal-muscle injury repair, and intraperitoneal ovarian-cancer metastasis \u2014 all without adverse effects up to 60\u00a0mg\/kg\/d. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Inibi\u00e7\u00e3o do NNMT e o Eixo NAD<sup>+<\/sup>\/SAM<\/h2>\n<p>O mecanismo do 5-Amino-1MQ \u00e9 o mais caracterizado de qualquer inibidor de NNMT de pequena mol\u00e9cula na literatura publicada:<\/p>\n<ul>\n<li><strong>Inibi\u00e7\u00e3o competitiva no local do substrato da NNMT<\/strong> \u2014 O 5-Amino-1MQ liga-se ao bolso do substrato de nicotinamida da NNMT, competindo com o substrato natural de nicotinamida e impedindo a transfer\u00eancia de metila\u00e7\u00e3o impulsionada por SAM. Estruturas de co-cristal publicadas em 2018 confirmaram a ocupa\u00e7\u00e3o direta do canal do substrato. IC<sub>50<\/sub> = 1,2 \u00b5M em concentra\u00e7\u00f5es de cofisiologicamente relevantes (50 \u00b5M SAM, 100 \u00b5M nicotinamida).<\/li>\n<li><strong>Poupan\u00e7a do pool de precursores de NAD<sup>+<\/sup> \u2014 A nicotinamida que n\u00e3o \u00e9 metilada pela NNMT permanece dispon\u00edvel para a via de salvamento NAMPT-NMNAT, onde \u00e9 convertida em NMN e depois em NAD<\/strong> \u2014 A nicotinamida que n\u00e3o \u00e9 metilada pela NNMT permanece dispon\u00edvel para a via de salvamento NAMPT-NMNAT, onde \u00e9 convertida em NMN e depois em NAD<sup>+<\/sup>. As c\u00e9lulas com elevada express\u00e3o de NNMT apresentam NAD<sup>+<\/sup> a deple\u00e7\u00e3o que o tratamento com 5-Amino-1MQ demonstrou reverter parcialmente em estudos publicados \u2014 tornando o composto mecanicamente distinto do NAD<sup>+<\/sup> precursores (NMN, NR, nicotinamida) que aumentam o reservat\u00f3rio a partir de cima em vez de reduzirem a taxa de consumo de nicotinamida.<\/li>\n<li><strong>Efeitos de poupan\u00e7a de SAM-pool e metila\u00e7\u00e3o subsequente<\/strong> \u2014 Each NNMT-catalysed reaction also consumes one SAM molecule, generating SAH. Inhibition of NNMT therefore raises intracellular SAM and lowers SAH, increasing the SAM:SAH ratio \u2014 the cellular methylation potential. This has been linked in published 3T3-L1 adipocyte studies to altered histone-methylation patterns at lipogenic gene loci and reduced de-novo lipogenesis.<\/li>\n<li><strong>Redu\u00e7\u00e3o da produ\u00e7\u00e3o de 1-metilnicotinamida (1-MNA)<\/strong> \u2014 1-MNA is the immediate product of the NNMT reaction. In published studies, plasma and tissue 1-MNA falls rapidly after 5-Amino-1MQ administration, providing a convenient pharmacodynamic biomarker for target engagement in in-vivo work.<\/li>\n<li><strong>Selectivity profile<\/strong> \u2014 O 5-Amino-1MQ n\u00e3o inibe as metiltransferases relacionadas GNMT (glicina N-metiltransferase), PNMT (feniletanolamina N-metiltransferase) ou COMT (catecol-O-metiltransferase), nem interfere com as enzimas de salvamento de NAD<sup>+<\/sup>-salvage NAMPT ou NMNAT. Este perfil de seletividade \u00e9 o que distingue o 5-Amino-1MQ dos inibidores de metiltransferase de espectro mais amplo e o torna a ferramenta farmacol\u00f3gica padr\u00e3o para dissecar a biologia espec\u00edfica da NNMT.<\/li>\n<\/ul>\n<p>The compound&#8217;s effects propagate from these biochemical primary actions into a small set of well-characterised cellular phenotypes: reduced 3T3-L1 adipocyte differentiation and lipogenesis (the most-cited in-vitro readout); increased muscle-satellite-cell proliferation and accelerated injury-repair in aged-mouse models; reduced peritoneal-tumour burden in ovarian-cancer metastasis models. Users should consult the primary literature (Neelakantan et\u00a0al. 2017\u20132019, Sampath et\u00a0al. 2018, subsequent NNMT-pathway reviews) for dose-response, kinetic, and species-specific parameters relevant to specific protocols. <\/p>\n<h2>Published Evidence<\/h2>\n<p>5-Amino-1MQ is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Bioqu\u00edmica e farmacologia do eixo NNMT<\/strong> \u2014 a ferramenta farmacol\u00f3gica can\u00f3nica para inibi\u00e7\u00e3o seletiva da NNMT em ensaios sem c\u00e9lulas, culturas de c\u00e9lulas prim\u00e1rias e trabalho in vivo em roedores; composto de refer\u00eancia padr\u00e3o para estudos de mecanismo de a\u00e7\u00e3o de novos esqueletos de inibidores da NNMT<\/li>\n<li><strong>NAD<sup>+<\/sup>Farmacologia do eixo \u2014 abordagem de poupan\u00e7a de substrato<\/strong> \u2014 mecanicamente distinta das abordagens de precursores de NAD<sup>+<\/sup>-precursor (suplementa\u00e7\u00e3o com NMN, NR ou niacinamida) que adicionam \u00e0 reserva a partir de cima; o 5-Amino-1MQ, em vez disso, reduz o consumo de precursores de NAD<sup>+<\/sup>-precursor a partir de baixo, bloqueando o maior sumidouro n\u00e3o recuper\u00e1vel (NNMT)<\/li>\n<li><strong>Adipocyte biology and obesity studies<\/strong> \u2014 a dose publicada de 20 mg\/kg\/dia em modelos de ratos com obesidade induzida por dieta foi relatada como reduzindo a massa adiposa, melhorando a toler\u00e2ncia \u00e0 glucose e diminuindo a acumula\u00e7\u00e3o lip\u00eddica hep\u00e1tica; o modelo can\u00f3nico de diferencia\u00e7\u00e3o 3T3-L1 mostra redu\u00e7\u00e3o da lipog\u00e9nese<\/li>\n<li><strong>Skeletal-muscle stem-cell biology and ageing studies<\/strong> \u2014 a dose publicada de 5\u201310 mg\/kg em modelos de ratos com les\u00e3o muscular induzida por cardiotoxina foi relatada como acelerando a prolifera\u00e7\u00e3o de c\u00e9lulas sat\u00e9lite e melhorando a capacidade regenerativa, particularmente em animais envelhecidos onde a express\u00e3o da NNMT est\u00e1 elevada<\/li>\n<li><strong>Cancer stromal-metabolism studies<\/strong> \u2014 5-Amino-1MQ has been used in published intraperitoneal HeyA8 ovarian-cancer-metastasis mouse models (up to 60\u00a0mg\/kg\/d) to reduce stromal NNMT activity and peritoneal tumour burden; also explored in stromal-targeted studies in pancreatic, prostate, and renal-cancer model systems where NNMT expression is high in the stromal compartment<\/li>\n<li><strong>Methylation-potential and one-carbon-metabolism studies<\/strong> \u2014 users studying the SAM:SAH ratio, global histone methylation, or DNA methylation can use 5-Amino-1MQ as a tool to perturb cellular methylation potential without directly inhibiting any DNA or histone methyltransferase<\/li>\n<li><strong>Mitochondrial bioenergetics combination studies<\/strong> \u2014 os protocolos por vezes combinam 5-Amino-1MQ (poupador de precursor de NAD) com<sup>+<\/sup>(suplementa\u00e7\u00e3o direta de precursor) ou <a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a> (suplementa\u00e7\u00e3o direta de precursor) ou <a href=\"https:\/\/medsbase.com\/pt-pt\/ss-31-elamipretide\/\">SS-31<\/a> Para um contexto mais amplo sobre o eixo NAD e os compostos de investiga\u00e7\u00e3o mitocondrial\/metab\u00f3lica neste cat\u00e1logo, consulte<\/li>\n<\/ul>\n<p>For broader context on NAD<sup>+<\/sup>-axis and mitochondrial \/ metabolic support compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a> (coenzima dinucle\u00f3tido oxidada, substrato central do transporte de eletr\u00f5es), <a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo regulador metab\u00f3lico derivado mitocondrial), <a href=\"https:\/\/medsbase.com\/pt-pt\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> (pept\u00eddeo mitocondrial direcionado com liga\u00e7\u00e3o \u00e0 cardiolipina), e <a href=\"https:\/\/medsbase.com\/pt-pt\/l-carnitine\/\">L-Carnitina<\/a> (transporte mitocondrial de \u00e1cidos gordos de cadeia longa). Navegue na lista completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">peptides &amp; compounds catalog<\/a> para compostos relacionados, ou consulte os <a href=\"https:\/\/medsbase.com\/pt-pt\/best-longevity-peptides\/\">longevity compounds<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> centrais. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks 5-Amino-1MQ in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cultura de c\u00e9lulas in vitro e titula\u00e7\u00e3o de curta dura\u00e7\u00e3o in vivo \u2014 ensaios de diferencia\u00e7\u00e3o 3T3-L1, farmacologia de c\u00e9lulas prim\u00e1rias, trabalho de resposta \u00e0 dose em coorte \u00fanica<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Concentra\u00e7\u00e3o interm\u00e9dia padr\u00e3o \u2014 protocolos in vivo de obesidade induzida por dieta em roedores (20 mg\/kg\/d durante 4\u20138 semanas), estudos de regenera\u00e7\u00e3o de les\u00f5es musculares, tamanhos de amostra de coorte interm\u00e9dia<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-throughput \/ extended-cycle protocols \u2014 large-cohort metabolic studies, multi-arm cancer-stroma studies (up to 60\u00a0mg\/kg\/d in HeyA8 ovarian-cancer model), long-arm chronic-dosing work; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical entity (lyophilized 5-amino-1-methylquinolinium iodide, \u226599% HPLC purity). The 50\u00a0mg vial provides the lowest per-mg cost for large in-vivo protocols (a single 50\u00a0mg vial covers roughly two weeks of 20\u00a0mg\/kg\/d dosing in a 20-g mouse, or about three days at 60\u00a0mg\/kg\/d in a 30-g rat). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Como Compara \u2014 5-Amino-1MQ vs NAD<sup>+<\/sup><\/h2>\n<p>O 5-Amino-1MQ e o <a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a> are both NAD-axis compounds, but they intervene at completely different points of the same metabolic loop. NAD<sup>+<\/sup> suplementa o pool de dinucle\u00f3tidos diretamente \u2014 \u00fatil quando o objetivo \u00e9 aumentar a disponibilidade de substratos redox\/sirtu\u00edna\/PARP a jusante. O 5-Amino-1MQ bloqueia o consumo terminal de nicotinamida catalisado pela NNMT \u2014 \u00fatil quando o objetivo \u00e9 retardar o esgotamento do pool de<sup>+<\/sup> precursor pool from cellular methylation-axis crosstalk. The two compounds are mechanistically complementary, and protocols sometimes combine them to dissect upstream-substrate (NAD<sup>+<\/sup>) vs contribui\u00e7\u00f5es de poupan\u00e7a de precursor a jusante (5-Amino-1MQ) para a produ\u00e7\u00e3o do eixo NAD. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">5-Amino-1MQ<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">NAD<sup>+<\/sup><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe qu\u00edmica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sal de am\u00f3nio quatern\u00e1rio de quinolinium de pequena mol\u00e9cula<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Coenzima dinucleot\u00eddica (adenina + nucleot\u00eddeos de nicotinamida unidos por difosfato)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">286,11 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">663.43 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Ponto de interven\u00e7\u00e3o no eixo NAD<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bloqueia o consumo de nicotinamida pela NNMT (retarda a deple\u00e7\u00e3o do precursor a partir de baixo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Adiciona diretamente \u00e0 piscina de dinucle\u00f3tidos (aumenta o substrato a partir de cima)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lipog\u00e9nese em adip\u00f3citos, repara\u00e7\u00e3o de c\u00e9lulas sat\u00e9lite musculares, metabolismo do estroma cancer\u00edgeno, farmacologia do eixo NNMT<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Biologia das sirtu\u00ednas, longevidade, envelhecimento celular, regula\u00e7\u00e3o redox do eixo NAD<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Seletividade<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Alto \u2014 n\u00e3o inibe GNMT, PNMT, COMT, NAMPT ou NMNAT<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">n\/a (NAD<sup>+<\/sup> \u00e9 o substrato natural)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estabilidade no plasma<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Est\u00e1vel \u2014 horas de meia-vida; suporta dosagem oral, IP e IV<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Inst\u00e1vel \u2014 minutos de meia-vida em solu\u00e7\u00e3o; oxida e degrada rapidamente<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5\u201360 mg\/kg\/d em protocolos publicados em ratos (20 mg\/kg\/d mais comum para DIO; 60 mg\/kg\/d o mais alto testado sem efeitos adversos)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dezenas a centenas de mg (cultura celular: concentra\u00e7\u00f5es em \u00b5M)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Aprova\u00e7\u00e3o da FDA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No \u2014 compound only<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No \u2014 compound only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on NAD<sup>+<\/sup>-axis precursor consumption by NNMT, adipocyte lipogenesis, or muscle-stem-cell biology, 5-Amino-1MQ is the canonical pharmacological tool. For studies focused on direct NAD<sup>+<\/sup>-suplementa\u00e7\u00e3o em pool, biologia das sirtu\u00ednas ou regula\u00e7\u00e3o redox dependente de NAD, <a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a> \u00e9 o composto mais direcionado. Veja tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-pt\/mots-c\/\">MOTS-c<\/a> for mitochondrial-derived peptide-signalling studies and <a href=\"https:\/\/medsbase.com\/pt-pt\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin-binding mitochondrial-targeted studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com o nosso <a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, conservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo, congele frascos n\u00e3o abertos a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226512 meses a 2\u20138 \u00b0C). O 5-Amino-1MQ liofilizado \u00e9 substancialmente mais est\u00e1vel do que a maioria dos pept\u00eddeos liofilizados porque a estrutura de sal de quinolinium de pequena mol\u00e9cula n\u00e3o possui liga\u00e7\u00f5es amida ou pontes dissulfeto para hidrolisar. Proteja da exposi\u00e7\u00e3o prolongada \u00e0 luz direta. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injete \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril ou PBS est\u00e9ril pela parede lateral do frasco (n\u00e3o diretamente sobre o bolo liofilizado). Para um frasco de 5 mg, 1,0 mL de diluente produz uma concentra\u00e7\u00e3o de trabalho de 5 mg\/mL; 0,5 mL produz 10 mg\/mL. Para um frasco de 10 mg, 1,0 mL produz 10 mg\/mL; 2,0 mL produz 5 mg\/mL. Para um frasco de 50 mg, 1,0 mL produz 50 mg\/mL (o limite pr\u00e1tico de solubilidade em tamp\u00e3o aquoso); 5,0 mL produz um estoque de trabalho mais dilu\u00eddo de 10 mg\/mL. O 5-Amino-1MQ dissolve-se muito rapidamente com agita\u00e7\u00e3o suave \u2014 tipicamente dentro de 10\u201330 segundos \u2014 porque o sal de am\u00f4nio quatern\u00e1rio \u00e9 altamente hidrof\u00edlico e n\u00e3o possui estrutura dobrada para perturbar. Para trabalho de cultura de c\u00e9lulas in vitro, o DMSO tamb\u00e9m \u00e9 um solvente de reconstitui\u00e7\u00e3o adequado (estoque at\u00e9 100 mM); dilua solu\u00e7\u00f5es de trabalho em meios aquosos imediatamente antes do uso. Uma vez reconstitu\u00eddo em tamp\u00e3o aquoso, armazene o frasco a 2\u20138 \u00b0C e use dentro de 30 dias. Proteja da luz. Descarte se aparecer turva\u00e7\u00e3o, part\u00edculas ou mudan\u00e7a marcada de cor. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>O 5-Amino-1MQ \u00e9 um pept\u00eddeo?<\/h3>\n<p>N\u00e3o. O 5-Amino-1MQ \u00e9 um sal de am\u00f4nio quatern\u00e1rio de quinolinium de pequena mol\u00e9cula (MW 286,11 g\/mol como iodeto), <em>n\u00e3o<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/pt-pt\/nad\/\">NAD<sup>+<\/sup><\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/l-carnitine\/\">L-Carnitina<\/a> because it serves a complementary role in mitochondrial \/ metabolic \/ NAD-axis studies and is supplied in the same lyophilized vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>O que a inibi\u00e7\u00e3o da NNMT faz realmente nas c\u00e9lulas?<\/h3>\n<p>A NNMT (nicotinamida N-metiltransferase) consome tanto nicotinamida (o precursor do NAD)<sup>+<\/sup>) e S-adenosil-L-metionina (SAM, o doador universal de metilo) para produzir 1-metilnicotinamida (1-MNA) e S-adenosilhomociste\u00edna (SAH). Quando a NNMT \u00e9 inibida pelo 5-Amino-1MQ, ambos os substratos s\u00e3o poupados: a disponibilidade intracelular de NAD<sup>+<\/sup> aumenta (porque a nicotinamida est\u00e1 agora livre para ser recuperada por NAMPT-NMNAT em NMN e NAD<sup>+<\/sup>), and intracellular SAM rises while SAH falls (raising the cellular methylation potential \u2014 the SAM:SAH ratio). These two biochemical primary effects propagate into the cellular phenotypes documented in published studies: reduced adipocyte lipogenesis, accelerated muscle-stem-cell repair, and reduced cancer-stroma tumour-supportive metabolism. <\/p>\n<h3>Em que \u00e9 que o 5-Amino-1MQ difere do NMN, NR ou niacinamida?<\/h3>\n<p>NMN, NR e niacinamida s\u00e3o todos NAD<sup>+<\/sup>\u2014 aumentam a reserva de NAD<sup>+<\/sup> pool from above by supplying salvageable precursors. 5-Amino-1MQ does the opposite: it blocks the terminal consumption of nicotinamide by NNMT, sparing the precursor pool from below. Mechanistically, the two approaches are complementary \u2014 published combination has explored whether co-administration of a precursor (NMN or NR) with a sparing agent (5-Amino-1MQ) produces an additive or super-additive effect on NAD<sup>+<\/sup> em compara\u00e7\u00e3o com qualquer uma das interven\u00e7\u00f5es isoladamente. <\/p>\n<h3>What published dose ranges have been used in mouse studies?<\/h3>\n<p>The most-cited mouse-protocol dose is 20\u00a0mg\/kg\/d for diet-induced obesity studies (4\u20138 weeks of daily intraperitoneal or oral administration). The injury-repair muscle has used 5\u201310\u00a0mg\/kg. The HeyA8 ovarian-cancer-metastasis has used up to 60\u00a0mg\/kg\/d without adverse effects reported in the published studies. Users should consult primary literature (Neelakantan et\u00a0al. 2017\u20132019, Sampath et\u00a0al. 2018, subsequent NNMT-pathway reviews) for species-, model-, and endpoint-specific dosing guidance. <\/p>\n<h3>What routes of administration are used in published studies?<\/h3>\n<p>Intraperitoneal (IP) administration in rodents is the most-common route in published in-vivo studies because it provides reliable systemic exposure and is convenient for repeated daily dosing. Oral administration (gavage or drinking water) has also been used in chronic dosing protocols. Subcutaneous and intravenous routes are less common but are documented. For in-vitro work, the compound is added directly to culture medium at micromolar concentrations. <\/p>\n<h3>O 5-Amino-1MQ pode ser combinado com NAD<sup>+<\/sup>, MOTS-c, or SS-31 in protocols?<\/h3>\n<p>Yes \u2014 the four compounds target different layers of mitochondrial and NAD-axis biology and are commonly combined in studies that aims to dissect upstream-substrate vs downstream-electron-flux vs cardiolipin \/ inner-membrane structural contributions to mitochondrial output. They are chemically stable in solution together. Reconstitute each separately first to establish stability and concentration accuracy, then combine immediately before use rather than co-storing reconstituted vials. The most-studied combination in published literature is 5-Amino-1MQ with NAD<sup>+<\/sup> precursores (NMN ou NR) conforme descrito acima; as combina\u00e7\u00f5es com compostos pept\u00eddicos s\u00e3o menos publicadas mas mecanicamente racionais. <\/p>\n<h3>Porque \u00e9 que o 5-Amino-1MQ n\u00e3o foi aprovado pela FDA?<\/h3>\n<p>5-Amino-1MQ is a relatively recent tool compound (substrate-site selectivity was first published by Neelakantan et\u00a0al. in 2017) and has not entered human clinical development to date. The NNMT-inhibitor space is active in early-stage drug discovery \u2014 several second-generation NNMT inhibitor scaffolds are in preclinical development \u2014 but no compound in this class has yet completed human clinical trials. 5-Amino-1MQ remains the most-published reference tool for selective NNMT inhibition in clinical studies. <\/p>\n<h3>Como \u00e9 que a seletividade do 5-Amino-1MQ se compara com inibidores de metiltransferases de espectro mais amplo?<\/h3>\n<p>O 5-Amino-1MQ \u00e9 um inibidor direcionado ao local do substrato \u2014 liga-se \u00e0 bolsa do substrato de nicotinamida da NNMT e n\u00e3o interage com a bolsa do cofator SAM. Isto \u00e9 mecanicamente distinto dos inibidores de metiltransferases competitivos do SAM (como a sinefungina ou an\u00e1logos da metiltioadenosina), que t\u00eam como alvo a bolsa do cofator e, portanto, inibem uma ampla gama de metiltransferases. A abordagem direcionada ao local do substrato confere ao 5-Amino-1MQ a sua seletividade sobre a GNMT, PNMT, COMT e outras enzimas dependentes do SAM, e \u00e9 o que o torna \u00fatil como ferramenta para dissecar a biologia espec\u00edfica da NNMT, em vez de ser um inibidor pan-metiltransferase. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Compounds for NAD-Axis and Metabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/nad\/\"><strong>NAD\u207a<\/strong><\/a> \u2014 Oxidised dinucleotide coenzyme \u2014 direct NAD-pool supplementation studies<\/li>\n<li><a href=\"\/pt-pt\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived peptide \u2014 metabolic and insulin sensitivity<\/li>\n<li><a href=\"\/pt-pt\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 Pept\u00eddeo mitocondrial direcionado \u00e0 cardiolipina<\/li>\n<li><a href=\"\/pt-pt\/epitalon\/\"><strong>Epitalon<\/strong><\/a> \u2014 Pineal-axis tetrapeptide bioregulator \u2014 telomerase \/ longevity studies<\/li>\n<li><a href=\"\/pt-pt\/l-carnitine\/\"><strong>L-Carnitina<\/strong><\/a> \u2014 Transportador mitocondrial de \u00e1cidos gordos de cadeia longa \u2014 mol\u00e9cula pequena companheira<\/li>\n<li><a href=\"\/pt-pt\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, conservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Inibidor seletivo de pequenas mol\u00e9culas NNMT (nicotinamida N-metiltransferase)<br \/>\n\u2705 Direcionado ao local do substrato; IC\u2085\u2080 1,2 \u00b5M; n\u00e3o afeta GNMT\/PNMT\/COMT\/NAMPT\/NMNAT<br \/>\n\u2705 Aumenta os pools intracelulares de NAD\u207a e SAM ao poupar o consumo de precursores<br \/>\n\u2705 Reduz a lipog\u00e9nese em adip\u00f3citos 3T3-L1; atividade publicada em modelos de ratos DIO<br \/>\n\u2705 Small-molecule compound \u2014 not a peptide (MW 286.11, CAS 42464-96-0)<\/p>\n<p><strong>5-Amino-1MQ<\/strong> contains 5-amino-1-methylquinolinium iodide compound.<\/p>","protected":false},"featured_media":71430,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6479,6483,6484,6481,6480,6482],"class_list":["post-71421","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-5-amino-1mq","product_tag-longevity-research","product_tag-metabolic-research","product_tag-nad-precursor-sparing","product_tag-nnmt-inhibitor","product_tag-research-compound","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/71421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=71421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/71430"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=71421"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=71421"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=71421"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=71421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}